News from archerdx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 29, 2019, 06:00 ET ArcherDX Announces the Appointment of Steven J. Kafka, Ph.D. as Executive Chairman of the Board of Directors

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


May 15, 2019, 06:00 ET ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Mar 28, 2019, 06:00 ET ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Circulating Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Mar 05, 2019, 06:00 ET ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Feb 12, 2019, 06:00 ET ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Jan 30, 2019, 06:00 ET ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Jan 08, 2019, 06:00 ET ArcherDX's Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Oct 03, 2018, 08:02 ET Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration

ArcherDX, a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine ...


Sep 05, 2018, 08:05 ET ArcherDX, Inc. Names Former Foundation Medicine Executive Steven Kafka, Ph.D. to its Board of Directors

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Aug 28, 2018, 08:00 ET ArcherDX, Inc. Appoints Marvin H. Caruthers, Ph.D., to its Board of Directors

ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic...


Apr 12, 2018, 08:00 ET Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870...


Mar 26, 2018, 08:00 ET ArcherDX and Ambry Genetics to provide immune repertoire and CAR-T-related sequencing services

ArcherDX and Ambry Genetics® announced today a partnership wherein Ambry will provide biopharma sequencing services employing ArcherDX's...


Nov 14, 2017, 05:48 ET ArcherDX receives EN ISO 13485 certification for medical device quality management

ArcherDX announced today that it has earned ISO 13485:2003 & EN ISO 13485:2012 certification from the British Standards Institution (BSI). This ISO...


Nov 07, 2017, 05:48 ET ArcherDX, Celgene ink Worldwide Companion Diagnostic Agreement relating to Investigational Drug CC-122

ArcherDX announced today that it has signed an agreement to develop and commercialize a next-generation sequencing (NGS)-based oncology companion...


Aug 02, 2017, 08:42 ET ArcherDX expands blood-based mutation assay portfolio with new myeloid panels

ArcherDX, the leader in NGS-based gene fusion detection assays, today launched the Archer® VariantPlex® Core Myeloid panel, which is used to analyze...


May 15, 2017, 12:51 ET ArcherDX launches B Cell Receptor Sequencing Assays for Immune Repertoire Characterization at Immunology 2017

ArcherDX, the leader in NGS-based fusion assays, today announced the release of Archer® Immunoverse™ B Cell Receptor (BCR) assays to characterize the ...


Apr 04, 2017, 07:47 ET ArcherDX announces strategic partnership with Chinese firm HeliTec for NGS-based diagnostic development

ArcherDX, the leader in NGS-based oncology sequencing applications, and the precision medicine company HeliTec announced today a strategic...


Dec 01, 2016, 07:47 ET ArcherDX launches Immune Repertoire Sequencing Assays at ASH 2016

ArcherDX, the leader in NGS-based fusion assays, today announced the release of the Archer® Immunoverse™ immune repertoire sequencing assays. These...


Nov 14, 2016, 07:38 ET Anchored Multiplex PCR patent is issued to inventors at Massachusetts General Hospital

ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today the issuance of the first patent for...


Nov 10, 2016, 06:15 ET New partnership between Sophia Genetics and ArcherDX continues to democratize Data-Driven Medicine

Today, at the AMP 2016 Annual Meeting, Sophia Genetics, global leader in Data-Driven Medicine, and world-class Next-Generation Sequencing (NGS) assay ...


Oct 04, 2016, 09:17 ET Almac Diagnostics Partners with ArcherDX

Almac Group's Diagnostics business unit today announced its partnership with ArcherDX to provide FusionPlex® and VariantPlex™ NGS assays as part of...


Sep 22, 2016, 09:17 ET ArcherDX dives into liquid biopsy research with Reveal ctDNA™ 28 assay

ArcherDX, the leader in NGS-based gene fusions, has announced the addition of a liquid biopsy assay to their portfolio. Archer® Reveal ctDNA™ 28 is...


Aug 09, 2016, 08:21 ET ArcherDX NGS assays receive conditional approval by New York State

ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today that two Archer® FusionPlex® NGS...


Oct 13, 2015, 09:13 ET ArcherDX Launches NGS Solution for Comprehensive Lung and Thyroid Tumor Profiling

ArcherDX, Inc., announced an addition to its target enrichment panel offering—the Archer™ Comprehensive Thyroid and Lung (CTL) Assay. This assay...